Completed PHASE4 INTERVENTIONAL 1-arm NCT02078882

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis (PBC)

Abatacept For The Treatment Of Primary Biliary Cirrhosis With An Incomplete Biochemical Response To Ursodeoxycholic Acid

Sponsor: Bristol-Myers Squibb

Conditions Primary Biliary Cirrhosis

Interventions abatacept

Updated 11 times since 2017 Last updated: Mar 28, 2020 Started: Sep 30, 2014 Primary completion: Oct 31, 2018 Completion: Oct 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02078882, this PHASE4 trial focuses on Primary Biliary Cirrhosis and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 11 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 6 earlier versions

May 2020 — Jan 2021 [monthly]

Completed PHASE4
Apr 2020 — May 2020 [monthly]

Completed PHASE4
Nov 2018 — Apr 2020 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Jun 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE4
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Christopher Bowlus, MD

Data source: University of California, Davis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sacramento, United States